Related Experiment Video
Updated: Apr 19, 2026
09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
12.2K
Grey matter atrophy in patients suffering from multiple sclerosis
Ideggyogyaszati Szemle
|December 19, 2014
Summary
Grey matter atrophy is increasingly recognized in multiple sclerosis (MS) and correlates with disability. This review examines grey matter atrophy and the impact of disease-modifying therapies on brain atrophy in MS patients.
Area of Science:
- Neuroscience
- Radiology
- Neurology
Background:
- Multiple sclerosis (MS) is characterized by white matter lesions, but grey matter involvement is gaining recognition.
- Cortical lesions and grey matter atrophy are increasingly detectable with advanced imaging techniques.
- Grey matter atrophy is suggested to correlate closely with clinical disability in MS.
Purpose of the Study:
- To review current knowledge on grey matter atrophy in multiple sclerosis.
- To explore the relationship between grey matter atrophy and clinical disability.
- To summarize the effects of disease-modifying therapies on brain atrophy in MS.
Main Methods:
- Literature review of studies investigating grey matter atrophy in MS.
- Analysis of imaging approaches for depicting cortical lesions and estimating grey matter atrophy.
- Synthesis of findings on the correlation between grey matter atrophy and disability.
- Evaluation of data on the impact of disease-modifying therapies on brain atrophy.
Main Results:
- Grey matter atrophy is a significant feature in MS, often correlating with disability progression.
- Advanced imaging techniques enable better visualization and quantification of grey matter changes.
- Disease-modifying therapies may influence the rate of brain atrophy in MS patients.
Conclusions:
- Grey matter atrophy is a critical aspect of MS pathology and disability.
- Further research is needed to fully understand the therapeutic modulation of grey matter atrophy.
- Integrating grey matter assessments into MS management may improve patient outcomes.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
4
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
4
01:23Alzheimer Disease ll: Pathophysiology
2
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
2
01:26Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
01:29Alzheimer Disease l: Introduction
4
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
4
01:22Myasthenia Gravis ll: Pathophysiology
14
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
14
01:26Cross-bridge Cycle
125.8K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
125.8K